SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs & Pharmaceuticals - Quaterly Results

24 Aug 2024 Evaluate
The company's total revenue for the quarter ended June 2024 saw a slight change in the total revenue, having registered a total revenue of Rs. 3172.75 millions.The Total Profit for the quarter ended June 2024 of Rs. 418.75 millions grew from Rs.-1896.73 millions Operating profit Margin for the quarter ended June 2024 improved to 698.59% as compared to -1667.53% of corresponding quarter ended June 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202406 202306 % Var
Sales 3172.75 3156.14 0.53 3172.75 3156.14 0.53 3172.75 3156.14 0.53
Other Income 261.76 203.98 28.33 261.76 203.98 28.33 261.76 203.98 28.33
PBIDT 698.59 -1667.53 -141.89 698.59 -1667.53 -141.89 698.59 -1667.53 -141.89
Interest 62.06 41.69 48.86 62.06 41.69 48.86 62.06 41.69 48.86
PBDT 636.53 -1709.22 -137.24 636.53 -1709.22 -137.24 636.53 -1709.22 -137.24
Depreciation 93.82 74.00 26.78 93.82 74.00 26.78 93.82 74.00 26.78
PBT 542.71 -1783.22 -130.43 542.71 -1783.22 -130.43 542.71 -1783.22 -130.43
TAX 123.96 113.51 9.21 123.96 113.51 9.21 123.96 113.51 9.21
Deferred Tax -1.27 -8.22 -84.55 -1.27 -8.22 -84.55 -1.27 -8.22 -84.55
PAT 418.75 -1896.73 -122.08 418.75 -1896.73 -122.08 418.75 -1896.73 -122.08
Equity 286.13 286.13 0.00 286.13 286.13 0.00 286.13 286.13 0.00
PBIDTM(%) 22.02 -52.83 -141.67 22.02 -52.83 -141.67 22.02 -52.83 -141.67

Akums Drugs & Pharma Share Price

535.95 1.85 (0.35%)
22-Apr-2026 11:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.85
Dr. Reddys Lab 1220.20
Cipla 1231.15
Zydus Lifesciences 930.70
Lupin 2313.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×